These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 23006540

  • 21. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
    Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N.
    BMC Health Serv Res; 2014 Sep 22; 14():419. PubMed ID: 25245666
    [Abstract] [Full Text] [Related]

  • 22. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D.
    Prim Care Diabetes; 2010 Jul 22; 4(2):113-7. PubMed ID: 20444662
    [Abstract] [Full Text] [Related]

  • 23. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.
    Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.
    Pharmacotherapy; 2009 Nov 22; 29(11):1280-8. PubMed ID: 19873688
    [Abstract] [Full Text] [Related]

  • 24. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS.
    Diabetes Obes Metab; 2018 Aug 22; 20(8):1921-1927. PubMed ID: 29652101
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 Aug 22; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

  • 26. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL, Sauriol L, Minshall ME.
    Appl Health Econ Health Policy; 2010 Aug 22; 8(4):267-80. PubMed ID: 20578781
    [Abstract] [Full Text] [Related]

  • 27. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S, Wu Y.
    Front Public Health; 2023 Aug 22; 11():1201818. PubMed ID: 37744474
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U, Ekman M, Granström O, Bergenheim K, McEwan P.
    Prim Care Diabetes; 2015 Feb 22; 9(1):39-47. PubMed ID: 24840612
    [Abstract] [Full Text] [Related]

  • 29. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar 22; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

  • 30. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr 22; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L.
    Curr Med Res Opin; 2017 Feb 22; 33(2):359-369. PubMed ID: 27817216
    [Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L.
    J Med Econ; 2013 Feb 22; 16(4):468-78. PubMed ID: 23384160
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.
    J Med Econ; 2012 Feb 22; 15(6):1039-50. PubMed ID: 22533526
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN.
    J Manag Care Spec Pharm; 2021 Apr 22; 27(4):455-468. PubMed ID: 33769850
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.